News Agency
The Times

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

  • Written by PR Newswire
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

Trial results anticipated in early Q3 this year

SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept,...

Read more: Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion